Protalex Receives Third Interim Review from Independent Data Safety Monitoring Committee in its Phase 1b Trial of PRTX-100 in Rheumatoid Arthritis July 23, 2013
Protalex Reports Positive Interim Review of Phase 1b Trial of PRTX-100 in Rheumatoid Arthritis by Independent Data Safety Monitoring Committee May 22, 2013
Protalex to Continue Phase 1b Trial of PRTX-100 in Patients with Active Rheumatoid Arthritis Following Data Safety Monitoring Committee Review March 7, 2013
Protalex, Inc. Announces Dosing Of First Patient In U.S. For New Trial Of PRTX-100 In Patients With Active Rheumatoid Arthritis November 29, 2012
Protalex, Inc. Completes Analysis of Data from Phase 1b Dose Escalation Study of PRTX-100 in Patients with Active Rheumatoid Arthritis August 29, 2012
Protalex, Inc. Findings from Phase 1b Dose Escalation Study of PRTX-100 in Patients with Active Rheumatoid Arthritis July 26, 2012
Protalex, Inc. Announces Completion of Dosing Patients in 4th Cohort of Its Phase 1b Dose Escalation Study of PRTX-100 in Patients With Active Rheumatoid Arthritis January 17, 2012
Protalex, Inc. Announces Enrollment of First Patients in 4th Cohort of Its Ongoing Phase 1b Dose Escalation Study of PRTX-100 in Patients With Active Rheumatoid Arthritis June 27, 2011
Protalex, Inc. Announces Enrollment of First Patients in 3rd Cohort of Its Ongoing Phase 1b Dose Escalation Study of PRTX-100 in Patients With Active Rheumatoid Arthritis March 3, 2011
Protalex, Inc. Announces 1 for 5 Reverse Stock Split and Preferred Stock Authorization December 7, 2010
